EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Oncorus's enterprise value is $27.56 Mil.
Oncorus's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-69.70 Mil. Therefore, Oncorus's EV-to-EBITDA for today is -0.40.
The historical rank and industry rank for Oncorus's EV-to-EBITDA or its related term are showing as below:
ONCR's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.14 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-26), Oncorus's stock price is $0.126.
Oncorus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-3.490. Therefore, Oncorus's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Oncorus EV-to-EBITDA Historical Data
The historical data trend for Oncorus's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oncorus's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncorus's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncorus's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Oncorus's EV-to-EBITDA falls into.
Oncorus EV-to-EBITDA Calculation
Oncorus's EV-to-EBITDA for today is calculated as:
Oncorus's current Enterprise Value is $27.56 Mil.
Oncorus's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncorus (OTCPK:ONCR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Oncorus's share price for today is $0.126.
Oncorus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Oncorus's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-021 and ONCR-788 which are based on coxsackievirus A21 or CVA21, and Seneca Valley Virus, or SVV, respectively.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ONCR has been successfully added to your 